We are having a green opening after back to back green days, which is pretty rare this year. We have obviously been due for a bounce and whether this is the bottom or a dead cat bounce is yet to be determined. This move is driven by short covering (the most shorted stocks are greatly […]
January 21 Biotech Update
So we have some biotech to talk about (finally) and the sector had a nice rally off the lows yesterday but we are not out of the woods by a country mile. At this point, however, it looks to be setting up as at least a tradable bounce but more ideally we would want it […]
November 25 Biotech Update
Trading is slow this week but news is not. Yesterday was better but I still think it is too early to call the sector back but at the very least I believe is has found its footing. Interestingly it seems that the SMID caps are outperforming the larger caps (finally) although they have a lot […]
August 31 Biotech Update
Looks like a slightly lower start to the week. Macro still obviously matters but the size of the moves seems to be decreasing. I find it interesting that the weakness comes after Fisher had a relatively hawkish Fed talk at Jackson Hole, where he noted that the Fed could raise rates before they saw inflation. […]
August 28 Biotech Update
I was busy for a day and the market does great but I come back and we have a gap lower. Sorry. In all seriousness, however, the snap back rally needs to pause but given the sell-off, I think we need to see the market shake off the gap lower and end higher today. We […]
August 21 Biotech Update
So it is obviously getting rough and we got our first peeks of panic yesterday. Most everyone seems to think that the worst is yet to come and I would not be surprised to see even more downside but obviously the contrarian in me wants to move to the other side of the boat when […]
August 20 Biotech Update
Another gap lower but the market remains in a rut refusing to breakdown or breakout. As I have said before, 2015 has been a year of churn and that is going to end up being really robust support for a breakout or really strong resistance for a breakdown. At this point, there is not a […]
July 6 Biotech Update
A pretty quiet start to the week (at least in terms of bio news). Obviously we have all the Greek drama but despite fears of the worst, the opening was not too bad and stocks seem to be rallying with bios taking the lead. While it is way too early to read into the price […]
Chimera Research Group Catalyst Summary for April 2015
At the end of each month Chimera Research Group provides you with a monthly summary of ten notable catalysts/events that have been completed during the past month. APRIL 2015: Gilead Sciences (NASDAQ: GILD) exceeded analyst expectations reporting $7.6 billion in first quarter revenue , including $4.55 billion from their HCV portfolio of Harvoni and Sovaldi. Revenue […]
April 13 Biotech Update
Happy merger Monday- well, happy Monday at least. The sector is off to a good start this week despite another dearth of deals this morning. It does worry me a little that the current expectation is that we will see mergers every Monday as the sector should ideally move on fundamentals and not quick merger […]
March 9 Biotech Update
A slow news start to the week and a weak start to the trading as the sector is again underperforming the broader markets. Despite the recent weakness, I am still not finding the screaming buy values. We are getting to the point where we had the large correction last year that convinced everyone that the […]
February 20 Biotech Update
As much as I have disliked this recent move higher in terms of not trusting it, you have to respect how well the sector is climbing the wall of worry. My hunch is that we are going to start to see another round of bubble trouble pronouncements. Clearly the sector is not a cheap as […]
January 23 Biotech Update
It has been sort of a mixed bag with the sector despite some decent macro tailwinds with the European QE program. I am not saying the sector has been bad but I would have expected it to take more of a leadership position in the move higher whereas it seemed more to have been dragged […]
January 2 Biotech Update
It is a good start to the New Year and it is only a matter of time until we start seeing facts talking about years in which the market opened higher end positive X% of the time. In any case, it is nice to see a positive start to the year and it will be […]
December 15 Biotech Update
A slow news start to the week and perhaps we are getting into the holiday doldrums a little early. In addition, the Santa Claus rally has been missing and that seems driven by the collapse in oil prices. This is obviously a boon to consumers around the globe and should be a tailwind for global […]
December 12 Biotech Update
The market is weak to open as a follow through on the selling yesterday. This feels like a reversal day but it is way too early to tell but either way I think we are going to get a sense of how stocks are going to trade into the end of the year. A day […]
December 8 Biotech Update
It has been a busy couple of days as expected and more news than can be adequately covered in one day, so today I will touch on what seems most interesting and/or near term actionable. Even then I will necessarily be leaving some important topics for later in the week so feel free to contact […]
April 29 Biotech Update- A Day of Steady Progress
The rollercoaster continues as we swing up and down in seemingly ever tighter time frames. In some ways, that seems good in that base building is a messy process with fairly rapid swings. I still think the sector needs the macro environment to be at least neutral in order to really set in a base […]
December 4 Biotech Update- Why Did I Buy Innate Pharma?
To be honest it has been a fairly boring week (for the most part) and the market seemed weak in the morning but not in a meaningful manner. There was more significant selling in the afternoon but I am not reading too much into it or the later day rally. Biotechs generally have been following […]
Week’s Option Activity (9/16~9/20)
The following stocks had notable activity in their options during the past week: $GERN (9/17): 5,000 OCT 2.00 strike Puts (stock at $2.26) were purchased for 0.14 or $70,000. This appears to be an opening trade where the buyer makes money if the shares trade below $1.86 by expiration. This could also be a long […]
